BioTheryX secures $92M to advance protein degradation oncology pipeline

By The Science Advisory Board staff writers

May 20, 2021 -- BioTheryX announced it has secured $92 million in series E financing to advance multiple molecular glues, PHM-based proteolysis-targeting chimeras (PROTACs), and monovalent degraders toward clinical development.

The funding was led by Farallon Capital Management. The company reported it plans to bring its first molecular glue program, BTX-1188, into the clinic by the end of 2021, and expand its platform of molecular glues, PROTACs, and monovalent degraders.

In addition, the company plans to advance the clinical development of its lead multikinase inhibitor, BTX-A51, for the treatment of acute myeloid leukemia, myelodysplastic syndromes, and solid tumors.

Cellectis, Sanofi partner on UCART clinical trials
Sanofi has agreed to supply anti-CD52 monoclonal antibody alemtuzumab for use in a lymphodepleting regimen in Cellectis-sponsored universal chimeric antigen...
CytoImmune, City of Hope ink CAR-NK cell therapy agreements
CytoImmune Therapeutics and City of Hope plan to collaborate on a portfolio of chimeric antigen receptor (CAR)-natural killer (NK) cell therapies through...
Machine-learning system ranks most effective cancer drugs
Scientists successfully trained an ensemble of machine-learning (ML) algorithms to rank clinically relevant cancer drugs based on the drugs' predicted...
Caribou nabs $115M to advance CRISPR-edited cell therapies
Caribou Biosciences has completed $115 million in financing to further develop its next-generation CRISPR technology platform and advance its pipeline...
$105M raised for Senti Bio to develop CAR-NK therapies
Leaps by Bayer, the investment arm of Bayer AG, and Senti Biosciences (Senti Bio) have announced a $105 million series B financing round to develop...

Copyright © 2021

Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter